Chemical Business Newsbase articles from February 2011, page 8

Chemical Business Newsbase archives from February 2011

Headwaters Incorporated launches redesigned corporate website.
February 24, 2011... Headwaters Inc, a diversified building products company dedicated to improving lives through innovative advancements in construction materials, announced the launch of its improved and redesigned corporate website: www.headwaters.com. The site...

Almirall and Kyorin announce a licensing agreement in Japan with aclidinium bromide.
February 24, 2011... Laboratorios Almirall SA and Kyorin Pharmaceutical Co Ltd announced on 24 Feb 2011 that they have entered into an agreement providing Kyorin exclusive rights to develop and commercialize aclidinium bromide in Japan for the treatment of COPD...

European Medicines Agency decision P/21/2011 of 25 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta), (EMEA-000689-PIP01-09-M02) in accordance with Regulation (EC) No 1901/2006 of the European P.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/21/2011 of 25 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta), (EMEA-000689-PIP01-09-M02). Changes to the agreed...

European Medicines Agency decision P/19/2011 of 25 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin phosphate monohydrate (Januvia) (EMEA-000470-PIP01-08-M03) in accordance with Regulation (EC) No 190.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/19/2011 of 25 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin phosphate monohydrate (Januvia) (EMEA-000470-PIP01-08-M03)....

European Medicines Agency decision P/15/2011 of 21 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ezetimibe (Ezetrol and associated names), (EMEA-000007-PIP01-07-M01) in accordance with Regulation (EC) No 1901/.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/15/2011 of 21 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ezetimibe (Ezetrol and associated names), (EMEA-000007-PIP01-07-M01)....

European Medicines Agency decision P/20/2011 of 25 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for alogliptin benzoate (EMEA-000496-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European P.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/20/2011 of 25 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for alogliptin benzoate (EMEA-000496-PIP01-08-M01). Changes to the agreed...

European Medicines Agency decision P/23/2011 of 25 Jan 2011 on the granting of a product specific waiver for tesamorelin (EMEA-001029-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/23/2011 of 25 Jan 2011 on the granting of a product specific waiver for tesamorelin (EMEA-001029-PIP01-10). A waiver for tesamorelin, lyophilisate for solution for injection,...

European Medicines Agency decision P/38/2011 of 17 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for N.meningitidis Outer Membrane Vesicles (OMV) from NZ 98/254 strain, N.meningitidis 287-953 purified antigen, N.m.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/38/2011 of 17 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for N.meningitidis Outer Membrane Vesicles (OMV) from NZ 98/254 strain,...

European Medicines Agency decision P/34/2011 of 28 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for house dust mites allergen extract from Dermatophagoides pteronyssinus and.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/34/2011 of 28 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for house dust mites allergen extract...

European Medicines Agency decision P/17/2011 of 21 Jan 2011 on the granting of a product specific waiver for perindopril arginine / indapamide
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/17/2011 of 21 Jan 2011 on the granting of a product specific waiver for perindopril arginine / indapamide / amlodipine besilate (EMEA-001048-PIP01-10). A waiver for perindopril...

European Medicines Agency decision P/22/2011 of 25 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for grass pollen allergen extract from Dactylis glomerata L., Anthoxanthum od.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/22/2011 of 25 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for grass pollen allergen extract...

European Medicines Agency decision P/25/2011 of 26 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for briakinumab (EMEA-000552-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliamen.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/25/2011 of 26 Jan 2011 on the acceptance of a modification of an agreed paediatric investigation plan for briakinumab (EMEA-000552-PIP01-09-M01). Changes to the agreed paediatric...

European Medicines Agency decision P/24/2011 of 26 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sotrastaurin acetate (EMEA-000093-PIP02-10) in accordance with Regulation.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/24/2011 of 26 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sotrastaurin acetate...

European Medicines Agency decision P/16/2011 of 21 Jan 2011 on the granting of a product specific waiver for nepafenac (Nevanac) (EMEA-000913-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/16/2011 of 21 Jan 2011 on the granting of a product specific waiver for nepafenac (Nevanac) (EMEA-000913-PIP01-10). A waiver for nepafenac (Nevanac), eye drops, suspension,...

European Medicines Agency decision P/18/2011 of 24 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lixisenatide (EMEA-000916-PIP01-10) in accordance with Regulation (EC) No.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/18/2011 of 24 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lixisenatide...

European Medicines Agency decision P/35/2011 of 28 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ozenoxacin (EMA-000981-PIP01-10) in accordance with Regulation (EC) No 19.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/35/2011 of 28 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ozenoxacin (EMA-000981-PIP01-10)....

European Medicines Agency decision P/26/2011 of 27 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for meropenem (EMEA-000898-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/26/2011 of 27 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for meropenem (EMEA-000898-PIP01-10). A paediatric investigation plan...

European Medicines Agency decision P/36/2011 of 28 Jan 2011 on the refusal of a product specific waiver for recombinant human granulocyte colony stimulating factor / recombinant human albumin fusion protein (EMEA-001042-PIP01-10) in accordance with Regula.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/36/2011 of 28 Jan 2011 on the refusal of a product specific waiver for recombinant human granulocyte colony stimulating factor / recombinant human albumin fusion protein...

European Medicines Agency decision P/37/2011 of 24 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for GLP-1 analogue linked to human IgG4 Fc-fragment (LY2189265) (EMEA-000783-.
February 24, 2011... On 24 Feb 2011, the European Medicines Agency published decision P/37/2011 of 24 Jan 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for GLP-1 analogue linked to human...

FDA: Advanced genomic test helps trace sources of foodborne illness outbreak: Next-generation sequencing provides important clues to traceback investigation.
February 24, 2011... US Food and Drug Administration (FDA) scientists successfully used a new genome sequencing test to retrospectively examine a 2009-2010 foodborne illness outbreak to help trace the source of the infection. A Salmonella Montevideo outbreak that...

Brazil miner Vale seen reporting 255% bigger 4Q profit.
February 24, 2011... Brazilian mining giant Vale expects to record GAAP net profit of $5.393 bn in the 4Q 2010 (+255% over 4Q 2009). Analysts also foresee a strong growth in iron ore shipment and increased sales of non-ferrous metals like nickel and copper in the 4Q...

Brazil's Klabin boosts investments in 2010 by 56.3% to R$ 386 M.
February 24, 2011... Brazilian paper producer and exporter Klabin S/A invested R$ 386 M in 2010 (+56.3% over 2009). The company utilized 47% of the total investment for paper business, 34% for forests, and remaining 18% for the conversion of finished products.

Brazil's Klabin moves to black in 4Q with R$ 225 M profit.
February 24, 2011... Klabin S/A, Brazilian paper producer and exporter recorded net profit of R$ 225.14 M for the 4Q 2010. Klabin's 4Q 2010 Ebitda stood at R$ 231.32 M (+6% over 4Q 2009). The company's net revenue increased by 16% to R$ 930.94 M in the 4Q 2010.

One portfolio for demanding surfaces: highlights for automotive and transportation coatings and industrial coatings at the European Coatings Show.
February 24, 2011... BASF's comprehensive range of pigments, resins and additives will be presented at the European Coatings Show (29-31Mar 2011) in Nuremberg, Germany, BASF will present its broad range of established products and technologies for both industries as...

BASF proposes dividend of EUR 2.20 per share.
February 24, 2011... The Board of Executive Directors of BASF SE has decided to propose to the Annual Meeting on 6 May 2011 a dividend of EUR 2.20/share for 2010. The decision is subject to approval by the company's Supervisory Board in its meeting on 3 Mar 2011. On...

BioSante Pharmaceuticals completes enrolment in LibiGel Phase III efficacy trial.
February 24, 2011... On 24 Feb 2011 BioSante Pharmaceuticals Inc announced that enrolment of subjects in the first of 2 pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials had been completed. The efficacy trials are being conducted under an...

Europe - Flint Group Print Media launches 2 new sheetfed offset blankets.
February 24, 2011... Flint Group announces the launch of 2 new blankets designed to deliver exceptional value and optimum print quality in defined sheetfed market segments. For packaging applications, Zenith 660 is a robust, long life blanket with excellent on-press...

Cutisin to invest nearly CEK 300 M in modernization in 2011.
February 24, 2011... Cutisin (Jilemnice, Czech Republic), artificial food casing manufacturer, will invest nearly CEK 300 M in modernization and extension of its production in 2011. Capacity of its plant could increase by 30% thanks to the modernization. Cutisin, a...

OTK Group plans to build a new hall worth CEK 100 M in 2011.
February 24, 2011... OTK Group (Kolin, Czech Republic), printed flexible packaging and graphic labels manufacturer, plans to build a new hall worth CEK 100 M in Kolin till the end of 2011. The new hall will enable OTK Group to extend its storage capacities. OTK...

Cepro guarantees the quality fuels supplies to petrol stations.
February 24, 2011... Cepro (Prague, Czech Republic), state oil products distributor, guarantees the quality fuels supplies to Czech petrol stations. Cepro controls nearly 70,000 samples/y of supplied fuels at its 13 modern laboratories. Cepro, wholly owned by the...

BASF: strong rise in sales in 2010; optimistic for 2011.
February 24, 2011... BASF says the economic recovery took place faster than everyone expected in 2010. BASF had sales up 26% in 2010 at EUR 63.9 bn and profit up 68% at EUR 8.1 bn. 4Q sales were up 25% at a record EUR 16.4 bn. 2011 has begun strongly for the...

Oil prices soar to 30-month high amid uprisings.
February 24, 2011... Oil prices climbed to their highest level in 30 months in London on 24 Feb 2011 as Libya's uprising reduced shipments and sparked fears of unrest spreading across the Middle East. Brent crude hit $119/bbl for the first time since Aug 2008, while...

Centrica signs GBP 2 bn gas deal with Qatar.
February 24, 2011... Centrica signed the UK's first long-term liquefied natural gas (LNG) contract with Qatar on 23 Feb 2011, to coincide with a trade mission to the Gulf led by Prime Minister David Cameron. Under the deal the British energy giant will import 2.4 M...

Sierra Leone: massive bauxite reserves discovered.
February 24, 2011... Sierra Leone Exploration and Mining Company (SLEMC) has discovered bauxite deposits of 140 M tonnes in the Port Loko and Kambia districts.

Beijing investing billions in oil and gas sector.
February 24, 2011... China's thirst for energy continues its unrestricted growth. This is forcing Beijing to adopt a multi-pronged approach. On the one hand, strategic oil storage depots with capacity of 85 M tonnes are to be erected. Also, China's industry giants...

Uzbekneftegaz invests $600 M in oil shale production.
February 24, 2011... Uzbekistan is to invest $850 M in oil shale production at Sangruntau. The project is due for completion by 2015. Specifically, Uzbekneftegaz is to invest $600 M in a production plant for processing oil shale into petroleum products. Capacity...

Croatia erecting solar power plant on the island of Pag.
February 24, 2011... Croatia's first solar power plant will probably be erected on the island of Pag in the Adriatic. Jadran Lux will invest up to EUR 15 M at the Poljava site. Capacity will be 3.8 MW. Croatia currently has five smaller photovoltaics plants with...

Council implementing Regulation (EU) No 167/2011 of 21 Feb 2011 terminating the partial interim review of the anti-dumping measures applicable to imports of certain polyethylene terephthalate originating, inter alia, in the Republic of Korea.
February 24, 2011... Adopted on 21 Feb 2011. The Council of the European Union, having regard to the Treaty on the Functioning of the European Union, having regard to Council Regulation (EC) No 1225/2009 of 30 Nov 2009 on protection against dumped imports from...

Commission Regulation (EU) No 168/2011 of 23 Feb 2011 amending Regulation (EU) No 107/2010 as regards the use of the feed additive Bacillus subtilis ATCC PTA-6737 in feed containing maduramycin ammonium, monensin sodium, narasin, or robenidine hydrochlori.
February 24, 2011... Adopted on 23 Feb 2011The European Commission, having regard to the Treaty on the Functioning of the European Union, having regard to Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 Sep 2003 on additives for use...

HTG Lands $15.7 M in Series D Financing.
February 24, 2011... HTG, Inc, provider of molecular technology solutions, .announced the closing of a Series D financing round led by new investor Novo A/S, Fletcher Spaght Ventures (FSV) a new investor. The new financing will be used to fuel the growth and...

Pfizer Teams With India Brewmaster in Return to $14 bn Insulin Market.
February 24, 2011... Biocon Ltd founder Kiran Mazumdar Shaw learned the intricacies of enzymes while studying how to make beer. Now Pfizer Inc, the world's largest drugmaker, is tapping that knowledge to revive its insulin business. The Bangalore, India based group...

FDA approves kidney disease label for Onglyza.
February 24, 2011... Bristol Myers Squibb Co and AstraZeneca PLC said they are expanding the label of their diabetes drug Onglyza, adding information about the drug's effects in patients with kidney failure. The companies revised the label after getting approval...

Marina Biotech Inc (formerly known as MDRNA Inc) reports interim results of their Phase II enabling toxicology study for CEQ508.
February 24, 2011... Marina Biotech Inc has completed a 9 month toxicology study in non human primates with its first drug candidate, CEQ508. CEQ508 is currently in a Phase Ib/IIa clinical development programme and is intended for the treatment of Familial...

Trophos successfully completes Phase I study for novel cardioprotective compound, TRO40303.
February 24, 2011... Trophos SA announced the successful completion of its Phase I dose escalation study of TRO40303, a novel mitochondria pore modulator. TRO40303 could become the first treatment to reduce the cardiac reperfusion injury that contributes...

OctoPlus expands development agreement with ESBATech on controlled release product for ophthalmic indications.
February 24, 2011... OctoPlus NV has signed a contract with ESBATech, an Alcon Biomedical Research Unit, to develop a controlled release formulation for one of its proprietary biological compounds for ophthalmic applications. The project includes process...

Living Cell Technologies Ltd's world leading encapsulating technology granted vital Australian patent.
February 24, 2011... Living Cell Technologies Ltd (LCT) has been granted a patent by the Australian Patent Office for IMMUPEL, LCT's industry leading technology for encapsulating living cells prior to transplantation. IMMUPEL is a novel, proprietary encapsulation...

Univercell Biosolutions acquires Ips Cell Patent Licence from iPS Academia Japan Inc.
February 24, 2011... Univercell Biosolutions SAS (UB) announced a worldwide non exclusive licensing agreement for iPS Academia Japan's iPSC (induced pluripotent stem cell) patent portfolio. Coupled with UB' own technology, the agreement will enable UB to provide...

Remedent Inc release: Glamsmile opens Shanghai Studio on 21 Feb 2011.
February 24, 2011... Remedent Inc opened its largest four chair facility in Shanghai on 21 Feb 2011. Remedent Inc specializes in the research, development, manufacturing and the marketing of oral care and cosmetic dental products. The company serves the professional...

SOHM's India based operations expand generic pharmaceutical line to include lifestyle disease drugs for antihypertension, cardiac disease, and cholesterol reduction.
February 24, 2011... SOHM Inc announced that SOHM's India based operations are expanding its generic pharmaceutical line to include lifestyle disease drugs for antihypertension, cardiac disease, and cholesterol reduction. SOHM Inc is a generic pharmaceutical...

Integrated DNA Technologies offers complete synthetic biology capabilities.
February 24, 2011... Integrated DNA Technologies (IDT) offers a completely confidential custom gene synthesis service. By manufacturing any genes, including hard to clone sequences, IDT provides a cost effective service, eliminating the outlay for construction,...

Med Biogene charged with fraud, and Precision Therapeutics charged with Tortious Interference in amended complaint by Signal Genetics.
February 24, 2011... Med Biogene Inc, a Vancouver-based life sciences company, has been charged with fraud, and Pittsburgh-based Precision Therapeutics Inc, was charged with tortious interference in an amended complaint filed by Signal Genetics in Supreme Court for...

Elan and Celgene enter into settlement and licence agreement related to abraxane.
February 24, 2011... Elan Corp and Celgene Corp announced that Elan subsidiary Elan PharmaInternational Ltd has entered into a settlement and licence agreement with Celgene Corp resolving the patent infringement litigation involving ABRAXANE. Elan initiated legal...

BioCryst awarded additional $55.0 M by the US Department of Health & Human Services to complete peramivir Phase III programme.
February 24, 2011... BioCryst Pharmaceuticals Inc announced that it has been awarded a $55.0 M contract modification by the US Department of Health & Human Services (HHS) intended to fund to completion the Phase III development of its neuraminidase inhibitor,...

Teleflex announces quarterly dividend payable 15 Mar 2011.
February 24, 2011... Teleflex Inc announced that its Board of Directors declared a quarterly cash dividend of $0.34/share of common stock. The dividend is payable 15 Mar 2011 to shareholders of record at the close of business on 4 Mar 2011. Teleflex is a global...

Patent lawsuit against GenMark Diagnostics dismissed.
February 24, 2011... GenMark Diagnostics Inc (GenMark) announced that Life Technologies Corp and Applied Biosystems LLC dismissed their patent infringement lawsuit against GenMark filed 19 Nov 2010 in the Southern District of California. The suit alleged that...

FDA grants Genentech a hearing on Avastin's use for metastatic breast cancer in the US.
February 24, 2011... Genentech announced the US Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has...

Colgate announces 9% dividend increase - effective 2Q 2010-2011.
February 24, 2011... Reflecting the company's positive outlook, the Board of Directors of Colgate-Palmolive Co increased the ongoing quarterly common stock cash dividend by 9%. The increase will be effective as of 2Q 2010-2011. The new rate of $0.58/share is up from...

Pharmaron closes over $40 M Series C financing.
February 24, 2011... Pharmaron Holding Ltd (Pharmaron) has closed a Series C financing round totalling more than $40 M from existing investors DCM, Legend Capital and others, along with new investor GL Capital Group. Pharmaron will use the new capital to strengthen...

BSD Medical announces the inclusion of hyperthermia and chemotherapy as a recommended cancer treatment for high risk sarcoma in the NCCN Practice Guidelines.
February 24, 2011... BSD Medical Corp announced the inclusion of hyperthermia and chemotherapy as a recommended cancer treatment for Stage IV (metastatic) sarcomas in the 'Practice Guidelines in Oncology' (V.2.2010), which is issued by the National Comprehensive...

CSL Behring receives FDA approval to extend shelf life of Hizentra to 30 months.
February 24, 2011... CSL Behring announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics Licence Application (sBLA) to extend the shelf life of Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, from 24 months to 30...

PolyMedix successfully completes Phase I exposure escalation safety study with PMX-30063 antibiotics.
February 24, 2011... PolyMedix Inc announced the successful completion of a Phase I exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063. The study results showed that PMX-30063 may be safely administered at a high dose for...

Amyris partners with Givaudan to develop key fragrance ingredient from Biofene.
February 24, 2011... Amyris Inc has entered into an agreement with Givaudan, the global leader in the fragrances and flavours industry, headquartered in Vernier, Switzerland. Under the agreement, Givaudan will develop a derivative of Biofene to be used as a building...

Unigene accelerates the development of its lead proprietary anorexigenic peptide UGP281 for obesity.
February 24, 2011... Unigene Laboratories Inc (Unigene) is accelerating the development of its lead proprietary anorexigenic peptide, UGP281. An anorexigenic peptide is one that diminishes or controls appetite and offers potential therapeutic benefit to morbidly...

BioSante Pharmaceuticals completes enrolment in LibiGel Phase III efficacy trial.(Clinical report)
February 24, 2011... BioSante Pharmaceuticals Inc (BioSante) has announced that enrolment of subjects in the first of two pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials has been completed. The efficacy trials are being conducted under an...

Salix anticipates receipt of FDA complete response letter on Xifaxan 550 mg tablets supplemental new drug application.
February 24, 2011... Salix Pharmaceuticals Ltd (Salix) has announced that based on a telephone conversation with the US Food and Drug Administration (FDA), the company anticipates receiving a complete response letter (CRL) on or before the 7 Mar 2011 PDUFA goal date...

Thermo Fisher Scientific signs agreements to sell Athena Diagnostics and Lancaster Laboratories businesses for a total of $940 M.
February 24, 2011... Thermo Fisher Scientific Inc (Thermo Fisher) has announced that it has signed definitive agreements to sell its Athena Diagnostics (Athena) and Lancaster Laboratories businesses for a total of $940 M in cash. Thermo Fisher reached an agreement...

Momentive introduces speciality product for solar industry applications.
February 24, 2011... As part of an extensive portfolio of speciality silicones for the rapidly growing solar industry, Momentive Performance Materials (Momentive) has introduced a one-component silicone, TSE3822. The new speciality product is an excellent candidate...

CIGNA declares dividend payable on 11 Apr 2011 and increases share repurchase authority.
February 24, 2011... On 23 Feb 2011, the board of directors of CIGNA Corp declared an annual dividend of $0.04/common share. The dividend is payable on 11 Apr 2011, to shareholders of record as of 11 Mar 2011. In addition, CIGNA's board increased the company's stock...

TheraBiogen Inc inks deal with Miami Heat and Walgreens.
February 24, 2011... TheraBiogen Inc has entered into a partnership with the Miami Heat and South Florida Walgreens. Through a relationship with JumpStart Inc, TheraMax was chosen as an official partner of a programme between the Miami Heat and Walgreens. The...

Government sets export target of $450 bn by 2013-2014: Releases draft strategy paper, seeks inputs by 23 Mar 2011. [1 table in original article].
February 24, 2011... The Union Commerce Ministry has released a draft strategy paper to double goods exports to $450 bn by 2013-2014. The paper also proposes to reduce dependence on imports. The Ministry has set export targets for pharmaceuticals, basic chemicals...

Jyothy Laboratories eyes regional fabric care brands: Such brands seen capable of 'going national'.
February 24, 2011... The Rup 800 crores Mumbai-based FMCG firm Jyothy Laboratories has earmarked Rup 300 crores to acquire regional fabric care brands. In the past, the company acquired two fabric whitener brands namely, Morelight and Ruby and has increased the...

Importer of controlled substances; notice of application (Sigma Aldrich Manufacturing LLC).
February 23, 2011... Sigma Aldrich Manufacturing LLC, 3500 Dekalb Street, St Louis, MO, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 4 Jan 2011 to be registered as an importer of 57 basic classes of controlled substances in...

Manufacturer of controlled substances; notice of registration (Halo Pharmaceutical Inc).
February 23, 2011... Halo Pharmaceutical Inc, 30 North Jefferson Road, Whippany, NJ, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 8 Oct 2010 to be registered as a bulk manufacturer of the basic classes of controlled substances...

Brazil Natura 4Q profit up 17.6% yoy to R$ 219.3 M.(Financial report)
February 23, 2011... Brazilian cosmetics manufacturer Natura reported net profit of R$ 219.3 M in the 4Q 2010 (+17.6% over 4Q 2009). Natura'S Ebitda for 4Q 2010stood at R$ 357.9 M (+21.4% over 4Q 2009). The company posted 4Q 2010net revenue of R$ 1.557 bn (+18.1%...

Brazil Ultrapar to pay R$ 251.95 M in dividends as from 17 Mar 2011.
February 23, 2011... Brazilian petrochemicals and natural gas holding company Ultrapar recommended a dividend of R$ 0.47/share payment resulting total payment of R$ 251.95 M, which will be paid as from 17 Mar 2011.

Brazil Ultrapar 4Q IFRS profit rises 81% yoy to R$ 247 M.(Financial report)
February 23, 2011... Brazilian petrochemicals and natural gas holding company Ultrapar recorded net profit of R$ 247 M for the 4Q 2010 (+81% over 4Q 2009). The company's cumulative net profit for 2010stood at R$ 765 M (+74% over 2009). The company reported 4Q 2010...

Brazil Petrobras 4Q profit seen higher at R$ 8.92 bn.(Financial report)
February 23, 2011... Brazil's petrochemical giant Petrobras expects to report net profit of R$ 8.92 bn for the 4Q 2010. The company estimated 4Q 2010 net revenue of R$ 56.66 bn (+19% over 4Q 2009) and Ebitda of R$ 16.16 bn (+11% over 4Q 2009).

Brazil's Fibria boosts exports in Jan by 87.7% to $136.2 M.
February 23, 2011... Brazilian eucalyptus-pulp producers Fibria recorded export of $136.217 M in Jan 2011 (+87.7% over Jan 2010). Brazil's pulp and paper producer, Suzano Papel e Celulose exported $93.975 M in Jan 2011 (+0.48% over Jan 2010). Meanwhile, Cenibra,...

Brazil Cosan concludes Zanin acquisition for R$ 90 M, below initial price.
February 23, 2011... Brazilian ethanol giant Cosan Acucar e Alcool (Cosan) has acquired sugar and alcohol mill Usina Zanin Acucar e Alcool (Zanin) for R$ 90 M. With this, Cosan will have Zanin's industrial and farming assets, and a greenfield project in Minas Gerais...

Pesticide products; registration applications (FMC Corp and others).
February 23, 2011... This notice, issued by the US Environmental Protection Agency (EPA), announces receipt of 11 applications to register new uses for pesticide products containing registered active ingredients, pursuant to the provisions of section 3(c) of the...

Manufacturer of controlled substances; notice of application (Johnson Matthey Pharmaceutical Materials Inc).
February 23, 2011... Johnson Matthey Pharmaceutical Materials Inc, Pharmaceutical Service, 25 Patton Road, Devens, MA, USA, made application by renewal to the US Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of basic classes of...

Manufacturer of controlled substances; notice of registration (Aldrich Chemical Co).
February 23, 2011... Aldrich Chemical Co Inc, DBA Isotec, 3858 Benner Road, Miamisburg, OH, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 19 Oct 2010 to be registered as a bulk manufacturer of 40 basic classes of controlled...

Manufacturer of controlled substances; notice of registration (Johnson Matthey Inc).
February 23, 2011... Johnson Matthey Inc, Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, NJ, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 19 Oct 2010 to be registered as a bulk manufacturer of basic classes...

Manufacturer of controlled substances; notice of registration (Chemic Laboratories Inc).
February 23, 2011... Chemic Laboratories Inc, 480 Neponset Street, Building 7, Canton, MA, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 14 Oct 2010 to be registered as a bulk manufacturer of cocaine, a basic class of controlled...